Physician
Hematology
Dr. Joseph R. Mikhael, MD
|
|
Give Review
Dr. Joseph R. Mikhael is an expert in the field of Hematology. Joseph Mikhael is also published. He has 57 publications published. The lastest publication: "Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.' Joseph Mikhael accepts all Medicare patients.
Publications
- Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed Myeloma.
- Quality of life and Disease understanding: impact of attending a patient-centered cancer symposium.
- Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation.
- Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple Myeloma.
- Identification of cereblon binding proteins and relationship with response and survival following pomalidomide and dexamethasone in multiple Myeloma.
- Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation.
- Cutaneous legionellosis: case report and review of the medical literature.
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple Myeloma: a randomized phase 2 study.
- Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple Myeloma following lenalidomide-based initial therapy.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- The clinical significance of cereblon expression in multiple Myeloma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell Lymphoma.
- A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multi...
- Immunoglobulin D amyloidosis: a distinct entity.
- Acute lung toxicity related to pomalidomide.
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory Disease.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple Myeloma.
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple Myeloma: a comparative analysis of 411 patients.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple Myeloma.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- The effects of deliberate practice and feedback to teach standardized handoff communication on the knowledge, attitudes, and practices of first-year residents.
- Pomalidomide: the new immunomodulatory agent for the treatment of multiple Myeloma.
- High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple Myeloma: results of a global phase 3b expanded access p...
- Age 40 years and under does not confer superior prognosis in patients with multiple Myeloma undergoing upfront autologous stem cell transmplant.
- Resident preparedness in discussing prognosis in patients with advanced lung cancer.
- Cost and mortality associated with hospitalizations in patients with Immune thrombocytopenic purpura.
- Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a Systematic review.
- Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive Disease characterized by rapid relapse and alkylating agent resistance.
- Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple Myeloma after autologous stem c...
- Using a pocket card to improve end-of-life care on internal medicine clinical teaching units: a cluster-randomized controlled trial.
- Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple Myeloma.
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell Lymphoma.
- IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.
- An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic Leukemia.
- Why do patients agree to a "Do not resuscitate" or "Full code" order? Perspectives of medical inpatients.
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
- A review of Immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists.
- The blue man: a novel cutaneous manifestation of Systemic amyloidosis.
- Incidence of extramedullary Disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
- Archimedean-like colloidal tilings on substrates with decagonal and tetradecagonal symmetry.
- Health care utilization and mortality among elderly patients with Myelodysplastic syndromes.
- Outpatient total body irradiation as a component of a comprehensive outpatient transplant program.
- Genetic risk identifies multiple Myeloma patients who do not benefit from autologous stem cell transplantation.
- Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a Systematic review.
- Canadian supportive care recommendations for the management of Anemia in patients with cancer.
- A typical atypical pneumonia.
- Canadian supportive care recommendations for the management of Neutropenia in patients with cancer.
- Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit.
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple Myeloma: high response rates in a phase II clinical trial.
- Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple Myeloma: a subset analy...
- Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple Myeloma: a meta-analysis.
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple Myeloma (MM).
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Central Nervous System Lymphoma
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Education
-
University of Ottawa Faculty of Medicine
Hospital
-
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
| NPI NUMBER | 1972781581 | |
| NPPES Provider LastName | MIKHAEL | |
| NPPES Provider FirstName | JOSEPH | |
| NPPES Provider ZIPCode | 852595404 | |
| NPPES Provider State | AZ | |
| Specialty Description | Hematology | |
| Total Claim Count | 176.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972781581 |
| Last Name Of The Provider | MIKHAEL |
| First Name Of The Provider | JOSEPH |
| View All |
Similar Doctors
|
|
Dr. Rafael Fonseca, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Irwin L. Levey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose F. Leis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mahesh Seetharam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruben A. Mesa, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Jasgit C. Sachdev, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric E. Prommer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig B. Reeder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen S. Anderson, MD |
|
|
Dr. Brenda J. Ernst, MD
This Doctor is OpenDoctor Recommended.
|